OBJECTIVES: To examine cost-effectiveness of oral triptan medications in Korea, and inform policy makers which triptan has the best/least value for money.   METHODS: We conducted literature reviews to identify economic and clinical values of triptan therapy. The clinical value of triptans was estimated based on randomized controlled trials (RCT), systematic reviews, and meta-analyses. We refer to previously published economic evaluation studies of triptan medications for selection of outcome measures and design of the simulation model. We built a decision tree model to explore cost-effectiveness of treating single attack in migraine patients. Outcome measures were 2 hour pain free, sustained freedom from pain, and sustained freedom from pain without side effects, based on previous studies and clinical practice guidelines. Cost of treating migraine was estimated by using Korea’s national health insurance claims database. Societal perspective was taken. One-way sensitivity analyses, as well as probabilistic sensitivity analyses, were conducted. RESULTS: Naratriptan, Sumatriptan, and Zolmitriptans are listed in the Korean National Health Insurance Drug List as of 2007. The efficacy of Naratriptan is inferior to Sumatriptan and Zolmitriptan in terms of 2-hour pain free, sustained freedom from pain, and sustained freedom from pain without adverse events. Cost-effectiveness analysis suggests that Naratriptan and Zolmitriptan are dominated by Sumatriptan in terms of the 3 observed outcome measures. Sensitivity analyses suggest that our results were robust under different assumptions. CONCLUSIONS:  Naratriptan and Zolmitriptan are dominated by Sumatriptan in terms of 2-hour pain free, sustained freedom from pain, sustained freedom from pain without side effects. Our results should be interpreted with caution, since Naratriptan and Zolimitriptan may have other values which could not be measured in our study.